An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Adakveo

Chemical Namecrizanlizumab-tmca
Dosage FormInjectable (intravenous; 10 mg/mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyNovartis
Approval Year2019

Indication

  • Adakveo is indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Adakveo (crizanlizumab-tmca) Prescribing Information2019Novartis
Document TitleYearSource
Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value.2020ICER
Document TitleYearSource
Systematic review of crizanlizumab: A new parenteral option to reduce vaso‐occlusive pain crises in patients with sickle cell disease.2020Pharmacotherapy
Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.2020BMJ Open
Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.2019Clinical Advances in Hematology & Oncology
Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.2017Blood Advances